Hotchkiss Brain Institute,
Department of Cell Biology and Anatomy,
Cumming School of Medicine,
Hotchkiss Brain Institute, Department of Cell Biology and Anatomy, Cumming School of Medicine
H. Artee Luchman has not added Biography.
If you are H. Artee Luchman and would like to personalize this page please email our Author Liaison for assistance.
Elevated mutant frequencies and predominance of G:C to A:T transition mutations in Msh6(-/-) small intestinal epithelium.
Oncogene Oct, 2002 | Pubmed ID: 12370835
Mutational-reporter transgenes rescued from mice lacking either Mgmt, or both Mgmt and Msh6 suggest that O6-alkylguanine-induced miscoding does not contribute to the spontaneous mutational spectrum.
Oncogene Aug, 2004 | Pubmed ID: 15208683
Mgmt deficiency alters the in vivo mutational spectrum of tissues exposed to the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK).
Carcinogenesis Apr, 2008 | Pubmed ID: 18281247
Temporally controlled prostate epithelium-specific gene alterations.
Genesis (New York, N.Y. : 2000) Apr, 2008 | Pubmed ID: 18395839
The pace of prostatic intraepithelial neoplasia development is determined by the timing of Pten tumor suppressor gene excision.
PloS one , 2008 | Pubmed ID: 19081794
An in vivo patient-derived model of endogenous IDH1-mutant glioma.
Neuro-oncology Feb, 2012 | Pubmed ID: 22166263
DNA hypermethylation and 1p Loss silence NHE-1 in oligodendroglioma.
Annals of neurology Jun, 2012 | Pubmed ID: 22718548
On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells.
Neuro-oncology Feb, 2013 | Pubmed ID: 23262510
Spontaneous loss of heterozygosity leading to homozygous R132H in a patient-derived IDH1 mutant cell line.
Neuro-oncology Aug, 2013 | Pubmed ID: 23757293
Prostate epithelium-specific deletion of the selenocysteine tRNA gene Trsp leads to early onset intraepithelial neoplasia.
The American journal of pathology Mar, 2014 | Pubmed ID: 24447801
Potent Targeting of the STAT3 Protein in Brain Cancer Stem Cells: A Promising Route for Treating Glioblastoma.
ACS medicinal chemistry letters Nov, 2013 | Pubmed ID: 24900612
Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation.
Clinical cancer research : an official journal of the American Association for Cancer Research Sep, 2014 | Pubmed ID: 25078279
Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Clinical cancer research : an official journal of the American Association for Cancer Research Nov, 2014 | Pubmed ID: 25316808
IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism.
Cancer research Aug, 2015 | Pubmed ID: 26045167
Precursor States of Brain Tumor Initiating Cell Lines Are Predictive of Survival in Xenografts and Associated with Glioblastoma Subtypes.
Stem cell reports Jul, 2015 | Pubmed ID: 26095605
Comparative genomic and genetic analysis of glioblastoma-derived brain tumor-initiating cells and their parent tumors.
Neuro-oncology Mar, 2016 | Pubmed ID: 26245525
Control of glioblastoma tumorigenesis by feed-forward cytokine signaling.
Nature neuroscience Jun, 2016 | Pubmed ID: 27110918
Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant .
Proceedings of the National Academy of Sciences of the United States of America 10, 2017 | Pubmed ID: 28916733
JoVE 소개
Copyright © 2024 MyJoVE Corporation. 판권 소유